Topical PEGylated azelaic acid nanohybrids: A lipid-polymer hydrogel system for sustained dermal delivery in rosacea management. Journal Abstract - Guideline Central

Topical PEGylated azelaic acid nanohybrids: A lipid-polymer hydrogel system for sustained dermal delivery in rosacea management.

Published: 2026 Apr 30

Authors

, , , , , ,

Abstract

Rosacea is a chronic inflammatory disorder of the central face characterized by persistent erythema, flushing, and inflammatory papules. Azelaic acid (Az) is a first-line topical therapy for papulopustular rosacea; however, its clinical efficacy is limited by poor aqueous solubility and restricted penetration across the stratum corneum. To overcome these limitations, PEGylated lipid-polymer hybrid nanoparticles (PALPHNs) encapsulating Az were developed and optimized using a Central Composite Design. The optimized PALPHNs exhibited a mean particle size of 179.6 ± 7.6 nm, narrow polydispersity (0.20 ± 0.03), stable zeta potential (-32.75 ± 1.4 mV), and high entrapment efficiency (92.13 ± 1.4%). Incorporation into a Carbopol hydrogel yielded a stable, skin-compatible formulation with physiological pH (5.84 ± 0.12). In vitro release studies demonstrated biphasic and sustained drug release, achieving 87.74 ± 0.002% cumulative release at 24 h compared with 72.21 ± 0.001% from conventional Az gel. Ex vivo permeation studies showed significantly enhanced Az penetration from the PALPHN gel (448.85 µg/cm²) vs the conventional gel (183.68 µg/cm²), with higher steady-state flux (18.21 vs 7.25 µg/cm²/h). Confocal laser scanning microscopy confirmed deeper epidermal penetration (∼44 µm). Safety assessment using HET-CAM and skin irritation studies showed good tolerability (PII = 0.875). In vivo evaluation using a croton oil-induced ear edema model demonstrated greater reduction in ear thickness (0.98 mm) compared with conventional Az gel (1.08 mm). Overall, the PALPHN hydrogel represents a promising nanocarrier system for topical rosacea therapy.

Keywords: Azelaic acid, Hydrogel, Lipid-polymer hybrid, PEGylated nanoparticles, Targeted drug delivery

Source

Colloids and surfaces. B, Biointerfaces

Publication Type

Journal Article

Language

English

PubMed ID

42070484

You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.